These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21389939)

  • 1. [Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
    Levin OS; Boĭko AN; Ivanov AK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 2):42-7. PubMed ID: 21389939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline: a review of its use in the management of Parkinson's disease.
    Oldfield V; Keating GM; Perry CM
    Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
    Stocchi F
    Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid onset of efficacy of rasagiline in early Parkinson's disease.
    Zambito Marsala S; Vitaliani R; Volpe D; Capozzoli F; Baroni L; Belgrado E; Borsato C; Gioulis M; Marchini C; Antonini A
    Neurol Sci; 2013 Nov; 34(11):2007-13. PubMed ID: 23636872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline.
    Siddiqui MA; Plosker GL
    Drugs Aging; 2005; 22(1):83-91; discussion 93-4. PubMed ID: 15663351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
    Rinaldi D; Assogna F; Sforza M; Tagliente S; Pontieri FE
    Neurol Sci; 2018 Jan; 39(1):141-143. PubMed ID: 28956175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.